Overview
ACH market data
Price History
ACH price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$14.31 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.46 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -39.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.19 – $5.85 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $86.8M · P/B 1.92 · P/S 0.03.
Company News
UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5Benzinga · Aug 13, 2026, 9:11 PM
Accendra Health shares are trading lower after Citigroup downgraded the stock from Buy to Neutral rating and lowered the price target from $4.5 to $1.5.Benzinga · Aug 11, 2026, 2:17 PM
Citigroup Downgrades Accendra Health to Neutral, Lowers Price Target to $1.5Benzinga · Aug 11, 2026, 12:21 PM
Accendra Health shares are trading lower after the company reported worse-than-expected Q2 financial results.Benzinga · Aug 10, 2026, 2:35 PM
12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · Aug 10, 2026, 12:06 PM
Accendra Health Q2 Adj. EPS $(0.19) Misses $(0.09) Estimate, Sales $613.200M Miss $627.306M EstimateBenzinga · Aug 10, 2026, 11:04 AM
Accendra Health Adopts Section 382 Rights Agreement To Protect Long-Term Shareholder Value By Preserving Its Net Operating Loss CarryforwardsBenzinga · Aug 10, 2026, 10:55 AM
8-K filing — ACCENDRA HEALTH INC/VA/ (ACH)SEC EDGAR · Aug 10, 2026, 10:50 AM
Accendra Health Lowers FY2026 Sales Guidance from $2.550B-$2.650B to $2.450B-$2.550B vs $2.574B EstBenzinga · Aug 10, 2026, 10:46 AM
Accendra Health’s President And CEO Edward Pesicka Plans To Retire By 2026 EndBenzinga · Aug 10, 2026, 10:36 AM